** Orthocell jumps as much as 21.1% to A$0.775, highest since May 9, 2019
** Stock logs biggest intraday pct jump since early October
** Biotech firm signs distributorship agreement with Singapore-based Device Technologies Asia for exclusive distribution of its nerve repair device Remplir
** OCC expects first sales of the device in first quarter of 2025
** Around 2.3 mln shares traded, 3.2x the 30-day avg
** Stock up ~87% YTD
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.